Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group.
about
Current and emerging azole antifungal agentsCryptococcus pneumonia presenting in an immunocompetent host with pulmonary asbestosis: a case reportPredictors of mortality and differences in clinical features among patients with Cryptococcosis according to immune statusIdentifying predictors of central nervous system disease in solid organ transplant recipients with cryptococcosisCryptococcus neoformans in organ transplant recipients: impact of calcineurin-inhibitor agents on mortalityA prospective descriptive study of cryptococcal meningitis in HIV uninfected patients in Vietnam - high prevalence of Cryptococcus neoformans var grubii in the absence of underlying disease.Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D studyMajor role for amphotericin B-flucytosine combination in severe cryptococcosis.Phenotypic switching of Cryptococcus neoformans can produce variants that elicit increased intracranial pressure in a rat model of cryptococcal meningoencephalitisClinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of america.Toward an integrated model of capsule regulation in Cryptococcus neoformansComparison and temporal trends of three groups with cryptococcosis: HIV-infected, solid organ transplant, and HIV-negative/non-transplantCryptococcosis in organ transplant recipients: an overview.In vitro interaction of flucytosine with conventional and new antifungals against Cryptococcus neoformans clinical isolates.First Description of Oral Cryptococcus neoformans Causing Osteomyelitis of the Mandible, Manubrium and Third Rib with Associated Soft Tissue Abscesses in an Immunocompetent Host.Approaches to antifungal therapies and their effectiveness among patients with cryptococcosisCurrent options in antifungal pharmacotherapy.Pulmonary cryptococcosis in patients without HIV infection: factors associated with disseminated disease.Tissue penetration of antifungal agents.Management of fungal lung disease in the immunocompromised.Consensus guidelines for the treatment of yeast infections in the haematology, oncology and intensive care setting, 2014.Pulmonary cryptococcosis in asymptomatic immunocompetent hosts.Pulmonary Cryptococcosis Presenting With Lung Mass: Report of 7 Cases and Review of Literature.Antifungal activity from Ocimum gratissimum L. towards Cryptococcus neoformans.Cryptococcal meningitis in non-HIV-infected patients in a Chinese tertiary care hospital, 1997-2007.Cryptococcal meningitis in a human immunodeficiency virus negative patient with follicular lymphoma.Therapy of Cryptococcal Meningitis in non-HIV-infected Patients.Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy.An official American Thoracic Society statement: Treatment of fungal infections in adult pulmonary and critical care patients.Recommendations for the treatment of established fungal infections
P2860
Q24550733-54EF4693-2632-49BB-8753-D93A1D0E23CDQ28387543-1F07E333-5AD6-4890-A75D-3CC051430245Q28488912-17B686B7-5253-4062-82BE-1FAF89FEF5AAQ30426041-A5E770E1-5693-43B9-8F30-69C4AA855572Q30438524-67F6C22B-A5C5-4C42-B27E-A22F1A3E1A87Q30495712-D5F08004-F7C3-4515-85BB-9A0CA432645BQ33272469-6A4B618A-C95D-4B12-8996-2B39854154DFQ33358131-F4B570F5-9DDB-4D12-9EBE-4D890C0E2D88Q33716133-7C192687-BFCE-475D-986E-C191FE42C371Q34020746-0CC122D7-F42A-4790-AD80-DB68C7AB3062Q34102709-903CD728-3237-44F8-807E-136B4C5B438FQ34399223-FA7AA099-8D03-4648-B957-B408B86AC137Q34802819-9B1B5069-6746-46D7-B473-F5AF5341361CQ36047748-2F418CEA-378F-4C38-B3B3-D07932D2AF1CQ36926992-658982E2-5C10-493D-87E3-1FA899F61754Q37026604-4F54B12A-CC86-491F-AD26-9E01A4F06853Q37151326-C7449C74-66B0-4913-B7D0-096520C4DB24Q37151983-DE1E525B-9EB7-4C25-91D2-BDD9F087CEF4Q37544911-27FAEAD5-B44A-477C-A8A8-DF1BA2169993Q37909774-CFA8CC40-8588-4D5C-9C36-C4BDB049EF0EQ38284461-398AA19E-4F57-4497-8717-D07C54BA2486Q38494332-112A472F-1811-426C-BF36-5E4F1E16DDDCQ38621332-40FC6376-AD4B-4FDD-907C-874BC8A88E19Q39170704-14D61586-FE6B-4C57-9B69-1D003EF8CB9FQ40361357-19A3C9F5-8A1A-4595-BCE9-75E2B4AC84E3Q42207337-15B8FF94-B92C-4108-A2EC-7B839CF6EA3CQ43413886-5CA34B27-1E47-4AED-9D80-DBA17C90EC09Q43690816-82DF0837-0BA1-42B8-8060-A89D3D094F53Q54394711-9416C177-A1EC-4DBD-8EFC-56D85D661A68Q58207332-B2FE5662-68FA-495F-BD56-08278B21C5D0
P2860
Comparison of the efficacy of amphotericin B and fluconazole in the treatment of cryptococcosis in human immunodeficiency virus-negative patients: retrospective analysis of 83 cases. French Cryptococcosis Study Group.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@en
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@nl
type
label
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@en
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@nl
prefLabel
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@en
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@nl
P2093
P1476
Comparison of the efficacy of ...... ch Cryptococcosis Study Group.
@en
P2093
P304
P356
10.1093/CLINIDS/22.SUPPLEMENT_2.S154
P407
P478
22 Suppl 2
P577
1996-05-01T00:00:00Z